Celgene Corporation (CELG) : Eos Focused Equity Management added new position in Celgene Corporation during the most recent quarter end. The investment management firm now holds 30,645 shares of Celgene Corporation which is valued at $3,487,707 , the company said in a statement filed on Aug 9, 2016 with the SEC.Celgene Corporation makes up approximately 3.54% of Eos Focused Equity Management’s portfolio.
Other Hedge Funds, Including , Oregon Public Employees Retirement Fund reduced its stake in CELG by selling 36,529 shares or 26.97% in the most recent quarter. The Hedge Fund company now holds 98,923 shares of CELG which is valued at $11,488,917. Celgene Corporation makes up approx 0.25% of Oregon Public Employees Retirement Fund’s portfolio.Klingenstein Fields Co boosted its stake in CELG in the latest quarter, The investment management firm added 6,864 additional shares and now holds a total of 143,502 shares of Celgene Corporation which is valued at $16,666,322. Celgene Corporation makes up approx 0.76% of Klingenstein Fields Co’s portfolio.Atalanta Sosnoff Capital reduced its stake in CELG by selling 9,515 shares or 3.54% in the most recent quarter. The Hedge Fund company now holds 258,969 shares of CELG which is valued at $27,997,139. Celgene Corporation makes up approx 0.91% of Atalanta Sosnoff Capital’s portfolio.Premier Asset Managment reduced its stake in CELG by selling 3,240 shares or 2.4% in the most recent quarter. The Hedge Fund company now holds 131,855 shares of CELG which is valued at $13,794,670. Celgene Corporation makes up approx 3.37% of Premier Asset Managment’s portfolio.
Celgene Corporation opened for trading at $112.17 and hit $112.84 on the upside on Wednesday, eventually ending the session at $112.55, with a gain of 0.34% or 0.38 points. The heightened volatility saw the trading volume jump to 37,33,670 shares. Company has a market cap of $87,239 M.
On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.
Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.
Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Companys primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.